These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37821217)

  • 21. Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol.
    Weiss RA; Weiss MA
    J Dermatol Surg Oncol; 1990 Sep; 16(9):800-4. PubMed ID: 2398199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Sclerotherapy with 3% polidocanol for hydrocele testis].
    Mizoguchi H; Imagawa M; Fukunaga Y; Nomura Y; Kubota M; Okita J
    Nihon Hinyokika Gakkai Zasshi; 1995 Dec; 86(12):1757-60. PubMed ID: 8717217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of sclerotherapy with polidocanol foam in comparison with fluid sclerosant in the treatment of first-grade haemorrhoidal disease: a randomised, controlled, single-blind, multicentre trial.
    Moser KH; Mosch C; Walgenbach M; Bussen DG; Kirsch J; Joos AK; Gliem P; Sauerland S
    Int J Colorectal Dis; 2013 Oct; 28(10):1439-47. PubMed ID: 23775099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized trial comparing 2 doses of polidocanol sclerotherapy for hydrocele or spermatocele.
    Jahnson S; Sandblom D; Holmäng S
    J Urol; 2011 Oct; 186(4):1319-23. PubMed ID: 21849198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polidocanol sclerotherapy for hydroceles and epididymal cysts.
    Sigurdsson T; Johansson JE; Jahnson S; Helgesen F; Andersson SO
    J Urol; 1994 Apr; 151(4):898-901. PubMed ID: 8126821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polidocanol sclerotherapy for painful venous malformations: evaluation of safety and efficacy in pain relief.
    Mimura H; Fujiwara H; Hiraki T; Gobara H; Mukai T; Hyodo T; Iguchi T; Yasui K; Kimata Y; Kanazawa S
    Eur Radiol; 2009 Oct; 19(10):2474-80. PubMed ID: 19440712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polidocanol (Varithena) for varicose veins.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):111-2. PubMed ID: 26218793
    [No Abstract]   [Full Text] [Related]  

  • 28. Late stroke after foam sclerotherapy.
    Hahn M; Schulz T; Jünger M
    Vasa; 2010 Feb; 39(1):108-10. PubMed ID: 20186684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polidocanol foam sclerotherapy in the treatment of hemorrhoidal disease in patients with bleeding disorders: a multicenter, prospective, cohort study.
    Salgueiro P; Rei A; Garrido M; Rosa B; Oliveira AM; Pereira-Guedes T; Morais S; Castro-Poças F
    Tech Coloproctol; 2022 Aug; 26(8):615-625. PubMed ID: 35217937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Embolia cutis medicamentosa of the foot after sclerotherapy.
    Geukens J; Rabe E; Bieber T
    Eur J Dermatol; 1999 Mar; 9(2):132-3. PubMed ID: 10066964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polidocanol Sclerotherapy for the Treatment of Pyogenic Granuloma in Children.
    Li J; Wu C; Song D; Wang L; Guo L
    Dermatol Surg; 2021 Jun; 47(6):802-804. PubMed ID: 33625133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sclerotherapy: a study comparing polidocanol in foam and liquid form.
    Uncu H
    Phlebology; 2010 Feb; 25(1):44-9. PubMed ID: 20118346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interim results of bleomycin-polidocanol foam sclerotherapy as a highly efficient technique for venous malformations.
    Yang X; Chen H; Gu H; Jin Y; Hu L; Hua C; Wang Y; Sun Y; Yu W; Lin X
    J Vasc Surg Venous Lymphat Disord; 2020 Nov; 8(6):1066-1073. PubMed ID: 32284311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polidocanol-foam treatment of varicose veins: Quality-of-life impact compared to conventional surgery.
    Sakugawa LS; Portela FSO; Louzada ACS; Portugal MFC; Teivelis MP; Mendes CA; Pinheiro LL; Silva MFAD; Fioranelli A; Wolosker N
    Clinics (Sao Paulo); 2024; 79():100346. PubMed ID: 38574572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postsclerotherapy hyperpigmentations. Chromated glycerin as a screen for patients at risk (a retrospective study).
    Georgiev M
    J Dermatol Surg Oncol; 1993 Jul; 19(7):649-52. PubMed ID: 8349903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polidocanol (aethoxysklerol) for sclerotherapy of superficial venules and telangiectasias.
    Goldman PM
    J Dermatol Surg Oncol; 1989 Feb; 15(2):204-9. PubMed ID: 2644330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stroke after varicose vein foam injection sclerotherapy.
    Forlee MV; Grouden M; Moore DJ; Shanik G
    J Vasc Surg; 2006 Jan; 43(1):162-4. PubMed ID: 16414404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indications for the sclerosing agent polidocanol (aetoxisclerol dexo, aethoxisklerol kreussler).
    Guex JJ
    J Dermatol Surg Oncol; 1993 Oct; 19(10):959-61. PubMed ID: 8408916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Skin Necrosis on the Face and Scalp Due To Sclerotherapy.
    Rota DD; Tamer F; Onder M; Erdogan FG; Yildirim D
    Dermatol Surg; 2018 Nov; 44(11):1459-1461. PubMed ID: 29677016
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial.
    Rabe E; Otto J; Schliephake D; Pannier F
    Eur J Vasc Endovasc Surg; 2008 Feb; 35(2):238-45. PubMed ID: 17988905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.